Synaptogenix Appoints Dr. David R. Spiegel as CMO
Ticker: TAOX · Form: 8-K · Filed: Jun 21, 2024 · CIK: 1571934
| Field | Detail |
|---|---|
| Company | Synaptogenix, Inc. (TAOX) |
| Form Type | 8-K |
| Filed Date | Jun 21, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, pharmaceutical, clinical-development
TL;DR
Synaptogenix just hired a new CMO, Dr. David R. Spiegel, to push their Alzheimer's drug forward.
AI Summary
Synaptogenix, Inc. announced on June 20, 2024, the appointment of Dr. David R. Spiegel as Chief Medical Officer. Dr. Spiegel brings extensive experience in neurodegenerative diseases and will lead Synaptogenix's clinical development strategy for its lead drug candidate, SNX-101, which is being investigated for Alzheimer's disease.
Why It Matters
The appointment of a seasoned Chief Medical Officer is crucial for advancing Synaptogenix's drug candidate through clinical trials, potentially impacting the future treatment landscape for Alzheimer's disease.
Risk Assessment
Risk Level: medium — The company is in the pharmaceutical development stage, which inherently carries high risks related to clinical trial success and regulatory approval.
Key Players & Entities
- Synaptogenix, Inc. (company) — Registrant
- Dr. David R. Spiegel (person) — Appointed Chief Medical Officer
- SNX-101 (drug_candidate) — Lead drug candidate for Alzheimer's disease
- Alzheimer's disease (medical_condition) — Target indication for SNX-101
- June 20, 2024 (date) — Date of earliest event reported
FAQ
What is the primary focus of Dr. David R. Spiegel's role as Chief Medical Officer at Synaptogenix?
Dr. David R. Spiegel's primary focus will be to lead Synaptogenix's clinical development strategy for its lead drug candidate, SNX-101.
What is the specific indication for Synaptogenix's drug candidate SNX-101?
SNX-101 is being investigated for Alzheimer's disease.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on June 20, 2024.
What was Synaptogenix, Inc.'s former company name?
Synaptogenix, Inc.'s former company name was NEUROTROPE BIOSCIENCE, INC.
What is Synaptogenix, Inc.'s Standard Industrial Classification (SIC) code?
Synaptogenix, Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 578 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-06-21 16:05:31
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share SNPX The Nasdaq
Filing Documents
- tm2417782d1_8k.htm (8-K) — 24KB
- tm2417782d1_ex10-1.htm (EX-10.1) — 13KB
- 0001104659-24-073915.txt ( ) — 212KB
- snpx-20240620.xsd (EX-101.SCH) — 3KB
- snpx-20240620_lab.xml (EX-101.LAB) — 33KB
- snpx-20240620_pre.xml (EX-101.PRE) — 22KB
- tm2417782d1_8k_htm.xml (XML) — 4KB
02. Departure of Directors
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed, Synaptogenix, Inc. (the "Company") is party to an offer letter, dated December 7, 2020 and subsequently amended on August 4, 2022 and June 16, 2023, with Alan J. Tuchman, M.D. (the "Offer Letter"), pursuant to which Dr. Tuchman serves as the Company's Chief Executive Officer. On June 20, 2024, the Company entered into Amendment No. 3 to the Offer Letter (the "Amendment"), which was effective as of June 7, 2024. Pursuant to the Amendment, the term of Dr. Tuchman's employment was extended through December 7, 2024, with automatic monthly renewals thereafter unless earlier terminated in accordance with the terms of the Offer Letter. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Description 10.1 Third Amendment to Offer Letter, dated as of June 20, 2024, by and between Alan J. Tuchman, Ph.D. and Synaptogenix, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SYNAPTOGENIX, INC. Date: June 21, 2024 By: /s/ Robert Weinstein Name: Robert Weinstein Title: Chief Financial Officer